One phase 1 trial assesses the safety and pharmacokinetics in HER2-positive advanced gastric cancers, gastroesophageal junction adenocarcinomas or breast cancers (clinicaltrials.gov identifier: NCT03368196). The gene discussed is ERBB2; the disease is breast cancer.